RemeGen Co., Ltd. (“RemeGen” or “the Company”) (9995.HK, SHA: 688331), a commercial-stage biotechnology company, recently released data from the Phase II clinical study of its proprietary novel fusion protein Telitacicept for the treatment of myasthenia gravis (MG) in Chinese patients, showing positive results.
For the multicenter, randomized, open-label Phase II clinical study, the subjects were adult patients diagnosed with myasthenia gravis (MG), who had tested positive for acetylcholine receptor antibodies, and were receiving standardized medical therapy. With a dosing cycle of once per week for 24 weeks, a total of 41 patients were recruited, where 29 of which were randomly assigned in the trial (14 assigned to the Telitacicept 160mg group and 15 in the 240mg group), and all completed the full duration. The primary efficacy endpoint of the study was the change in the Quantitative Myasthenia Gravis (QMG) test score at week 24 compared to the baseline.
The study showed a mean reduction of 7.7 points in the Telitacicept 160mg group and 9.6 points in the Telitacicept 240mg group (an improvement of 3 points in the QMG score is clinically significant, with an improvement of more than 5 points representing significant curative effects). It showed that Telitacicept can significantly improve the condition of patients and demonstrated good safety in the treatment of myasthenia gravis (MG).
“As a fully-integrated biopharmaceutical company committed to the discovery, development and commercialization of innovative and differentiated biologics for the treatment of autoimmune, oncology and ophthalmic diseases, our vision to become a leading player in the global biopharmaceutical industry is rapidly being realized,” said Dr. Jianmin Fang, CEO and Chief Scientific Officer of RemeGen.
“Leveraging our strong research and development platforms, we have discovered and developed a robust pipeline of more than ten drug candidates, among which, seven are in clinical development stage targeting over twenty indications. The latest Phase II clinical study results show the use of our proprietary novel fusion protein Telitacicept in the treatment of MG in Chinese patients has the potential to profoundly address the unmet clinical needs of countless patients in China and around the globe,” added Fang.
Currently, the most common treatment options for myasthenia gravis (MG) include cholinesterase inhibitors, glucocorticoids, immunosuppressants, where a large number of unmet clinical demands need to be addressed. RemeGen will continue to invest in the research and development of innovative drugs and provide solutions to the unmet clinical needs of patients suffering from life-threatening illnesses.
